CD274 and cancer: In the meantime, the release of chemotherapeutic drugs (e.g., doxorubicin (DOX), paclitaxel (PTX), camptothecin (CPT)), and immune checkpoint antibodies (e.g., anti‐CTLA‐4 anti‐PD‐1, anti‐PD‐L1 inhibitors), immune adjuvants, and enzymes further enhance anti‐tumor efficiency from aspects of cascade immune activator and chemotherapy.[65] Given the advantages of cancer‐specific accumulation, deep penetration, and high drug loading efficacy, srNPs are potent for improved synergistic immunotherapy.